Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant
Sponsored by Ayman Saad
About this trial
Last updated 4 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 2 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Failure to engraft platelets by day 30 (D30) after hematopoietic cell transplantation (HCT) defined as: Platelet count less than 20,000/uL and patient is still dependent on platelet transfusion support
- Patient must be able to start treatment with avatrombopag within 30-60 days following transplant
- Able to provide written informed consent from patient or legal representative
Exclusion Criteria
- Serious uncontrolled infections
- Steroid refractory graft versus host disease (GVHD)
- Patients with thrombotic microangiopathy
- Pregnant or lactating women
- Creatinine clearance < 30 ml/min
- Active thromboembolism requiring anticoagulation
- Unable to understand the investigational nature of the study or provide informed consent
- Evidence of disease relapse by flow cytometry of chimerisms
- Concomitant use of other thrombopoietin receptor agonists (TPO-RA) medication during the treatment phase of the study or two weeks prior to enrollment